ALNY 10-Q Quarterly Reports

Alnylam Pharmaceuticals, Inc. reported strong financial performance for the six months ended June 30, 2026, driven by significant growth in net product revenues, primarily from AMVUTTRA. The company achieved a substantial increase in net product revenues, up 94% year-over-year, reaching $2.21 billion, with AMVUTTRA sales more than doubling to $1.90 billion. This growth is largely attributed to the expansion of AMVUTTRA for ATTR-CM in the US and other global markets. While net revenues from collaborations decreased by 20%, this was primarily due to the completion of certain collaboration activities and the wind-down of research terms, partially offset by increased revenue from the Roche collaboration. The company reported a net income of $370.5 million for the six-month period, a significant improvement from a net loss of $90.5 million in the prior year, indicating a strong shift towards profitability. The balance sheet shows healthy liquidity with $1.71 billion in cash and cash equivalents and $1.60 billion in marketable debt securities.

Alnylam Pharmaceuticals, Inc. demonstrated significant financial performance in the first quarter of 2026, reporting a substantial increase in total revenues to $1.17 billion, primarily driven by a robust surge in net product revenues, which grew by 121% to $1.04 billion. This growth was largely attributed to AMVUTTRA, which saw a remarkable 187% increase in total net product revenues, notably in the U.S. for ATTR-CM treatment. Despite a rise in operating costs and expenses, which increased by 56% to $898.5 million, the company achieved a strong income from operations of $268.6 million, a significant improvement from the prior year's quarter. The company's balance sheet shows a healthy liquidity position with $1.71 billion in cash and cash equivalents. However, the increased interest expense due to liabilities related to the sale of future royalties and development funding, coupled with ongoing significant investments in research and development, indicates a continued focus on pipeline expansion. Management believes existing resources are sufficient for at least the next 12 months, but future capital needs may arise for continued commercialization and pipeline advancement.

Alnylam Pharmaceuticals, Inc. (ALNY) reported a strong third quarter of 2025, showcasing significant revenue growth driven by its TTR franchise, particularly AMVUTTRA, and substantial increases in collaboration revenues, largely due to a significant milestone payment from Roche for the zilebesiran program. Total revenues more than doubled year-over-year for both the quarter and the nine-month period, indicating robust commercial execution and successful strategic partnerships. The company demonstrated substantial progress in its financial position, with a significant increase in cash and cash equivalents, largely due to proceeds from the issuance of new convertible senior notes and strong operating cash flow. Despite increased operating costs and expenses, including higher R&D and SG&A spending to support pipeline advancement and commercial expansion, Alnylam achieved operating income and net income for the quarter, a notable improvement from the prior year's loss. The company also strategically managed its debt by repurchasing a portion of its 2027 convertible notes and issuing new 2028 notes, alongside establishing a new revolving credit facility, enhancing its financial flexibility. Key developments in the pipeline include positive results and initiation of Phase 3 trials for nucresiran and zilebesiran, respectively, alongside continued progress in other key programs. The company's commercial products, particularly AMVUTTRA, are showing strong growth, and collaborations with partners like Roche and Regeneron are contributing significantly to revenue, underscoring Alnylam's strategy of building a multi-product, global biopharmaceutical company.

Alnylam Pharmaceuticals, Inc. reported a significant increase in total revenues for the six months ended June 30, 2025, up 19% year-over-year to $1.37 billion. This growth was primarily driven by a substantial 47% increase in net product revenues, reaching $1.14 billion, largely attributable to the strong performance of AMVUTTRA, particularly in the treatment of ATTR amyloidosis with cardiomyopathy. ONPATTRO saw a decline in revenue, likely due to patient switching to AMVUTTRA. Conversely, collaboration revenues decreased by 54% to $160.7 million, mainly due to the recognition of a large milestone payment in the prior year's comparable period for the Regeneron collaboration, partially offset by a payment from Vir Biotechnology. Despite revenue growth, the company reported a net loss of $123.8 million for the six months, a widening from the $82.8 million loss in the same period of 2024. This increase in net loss, despite higher revenues, is due to a significant rise in operating costs and expenses, which grew by 19% to $1.37 billion, outpacing revenue growth. The company's balance sheet shows a healthy cash position of $1.11 billion as of June 30, 2025, providing sufficient liquidity for at least the next 12 months. The increase in cash is supported by strong net cash provided by operating activities, which, despite a decrease from the prior year, remains positive at $35.4 million. However, the company continues to incur substantial R&D and SG&A expenses, reflecting ongoing investments in pipeline development and commercialization efforts. The ongoing patent litigation with Moderna and Pfizer remains a notable contingent liability, with recent rulings unfavorable to Alnylam, although the financial impact is not yet quantifiable.

Alnylam Pharmaceuticals, Inc. reported solid top-line growth for the first quarter of 2025, with total revenues increasing by 20% year-over-year to $594.2 million. This growth was primarily driven by a significant 28% increase in net product revenues, reaching $468.5 million, largely due to strong performance from AMVUTTRA, which saw a 59% increase in total sales across regions. ONPATTRO's sales declined by 29%, attributed to patient switching to AMVUTTRA. While collaboration revenues decreased by 16% mainly due to a large milestone payment received in the prior year from the Roche collaboration, royalty revenue saw a substantial 149% increase, driven by higher royalties from Leqvio. The company narrowed its net loss to $57.5 million from $65.9 million in the prior year's first quarter, indicating progress towards profitability, although significant R&D and SG&A expenses continue to weigh on the bottom line. The company ended the quarter with a robust cash and cash equivalents balance of over $1 billion, providing ample liquidity.

Alnylam Pharmaceuticals, Inc. (ALNY) reported a net loss of $111.6 million for the third quarter of 2024, compared to a net income of $147.8 million in the same period last year. This shift is largely due to a significant decrease in collaboration revenues, primarily from the Roche collaboration, which included a substantial upfront payment recognized in Q3 2023. Despite the net loss, product revenues saw robust growth, increasing by 34% year-over-year to $420.1 million, driven by strong performance from AMVUTTRA and growth in GIVLAARI and OXLUMO, partially offset by a decline in ONPATTRO sales. For the nine months ended September 30, 2024, Alnylam reported a net loss of $194.4 million, an improvement from the $302.4 million net loss in the prior year period. Total revenues increased by 19% to $1.66 billion, with net product revenues up 34% to $1.20 billion. However, the company's operating costs and expenses also rose by 11% to $1.73 billion. The company ended the quarter with a strong cash position of $1.10 billion, providing ample liquidity for at least the next 12 months. Management remains focused on advancing its pipeline, with key submissions for AMVUTTRA in cardiomyopathy and positive interim results for mivelsiran in Alzheimer's disease.

Alnylam Pharmaceuticals, Inc. reported robust top-line growth in its second quarter of 2024, with total revenues increasing by 107% year-over-year to $659.8 million. This surge was primarily driven by a significant increase in net product revenues, which rose by 34% to $410.1 million, led by strong performance from AMVUTTRA. Collaboration revenues also saw a substantial increase, growing from $5.8 million in the prior year period to $227.3 million, largely due to the amended collaboration agreement with Regeneron Pharmaceuticals and milestone achievements with Roche. Despite the strong revenue growth, the company reported a net loss of $16.9 million for the quarter, an improvement from the $276.0 million net loss in the second quarter of 2023. This improved net loss reflects the significant increase in revenue and a more favorable cost of goods sold as a percentage of net product revenues. Research and development expenses increased by 18% year-over-year, reflecting ongoing investments in pipeline expansion, particularly for zilebesiran and mivelsiran. The company maintains a strong liquidity position with $971.2 million in cash, cash equivalents, and restricted cash as of June 30, 2024, which management believes is sufficient to meet operating needs for at least the next 12 months.

Alnylam Pharmaceuticals, Inc. reported a substantial increase in total revenues for the first quarter of 2024, driven by strong performance in both net product revenues and collaboration revenues. Net product revenues saw a 32% increase year-over-year, primarily fueled by the robust growth of AMVUTTRA, alongside continued strength from GIVLAARI and OXLUMO. Collaboration revenues more than doubled, largely due to revenue recognized from the Roche collaboration, including a significant milestone payment related to the zilebesiran program, and increased activity with Regeneron. Despite the revenue growth, the company reported a net loss of $65.9 million, an improvement from the previous year's loss of $174.1 million, indicating progress in narrowing the operational loss. Research and development expenses increased by 13%, reflecting continued investment in pipeline advancement, particularly for zilebesiran and the HELIOS-B study. Selling, general, and administrative expenses also rose, driven by marketing investments and headcount growth. The company's liquidity remains strong, with cash, cash equivalents, and marketable securities sufficient for at least the next 12 months, according to management.

Alnylam Pharmaceuticals, Inc. reported a significant increase in total revenues for the third quarter and first nine months of 2023, driven by strong growth in net product revenues and substantial collaboration revenues, particularly from the new Roche agreement and an early clinical milestone from Regeneron. Net product revenues saw a notable increase of 35% year-over-year in Q3, primarily due to the launch and uptake of AMVUTTRA, offsetting a decline in ONPATTRO sales as patients switched to the newer therapy. The company also reported positive momentum across its other key products, GIVLAARI and OXLUMO. Operationally, the company's focus remains on advancing its pipeline, with significant R&D expenses supporting various clinical programs. Despite an increase in Cost of Goods Sold, largely due to an inventory impairment related to ONPATTRO's ATTR cardiomyopathy indication, the company achieved a net income of $147.8 million in Q3 2023, a significant turnaround from a net loss in the prior year's quarter. This improved profitability reflects the substantial collaboration revenue and disciplined expense management. The company maintains sufficient liquidity and believes its current cash and cash equivalents will support operations for at least the next 12 months.

Alnylam Pharmaceuticals, Inc. reported a significant increase in total revenues for the second quarter of 2023, reaching $318.8 million, a 42% increase year-over-year, primarily driven by strong net product revenues. Net product revenues surged by 43% to $305.7 million, largely due to the successful launch and uptake of AMVUTTRA, alongside continued growth from GIVLAARI and OXLUMO. ONPATTRO revenue saw a decline, attributed to patient switches to AMVUTTRA. Collaboration revenues experienced a decrease, mainly due to revised assumptions for the Regeneron collaboration, while royalty revenue from Leqvio significantly increased. Despite revenue growth, the company reported a net loss of $276.0 million for the quarter, reflecting ongoing substantial investments in research and development and selling, general, and administrative expenses. The company's cash position remains robust, providing at least 12 months of operating runway.

Alnylam Pharmaceuticals, Inc. reported significant top-line growth in the first quarter of 2023, with total revenues increasing by 50% year-over-year to $319.3 million. This growth was driven by a substantial 48% increase in net product revenues, primarily due to the successful launch and uptake of AMVUTTRA in the U.S., alongside continued growth for GIVLAARI and OXLUMO. Collaboration revenues also saw a healthy increase of 41%, largely attributed to enhanced activity with Regeneron Pharmaceuticals. Despite the strong revenue performance, the company continued to operate at a net loss of $174.1 million, though this represents a 28% improvement compared to the same period last year, indicating progress in managing operational costs relative to revenue growth. Operationally, Alnylam is advancing its pipeline with ONPATTRO receiving FDA acceptance for an sNDA for ATTR amyloidosis cardiomyopathy, and AMVUTTRA continuing its global rollout. The company maintains a solid liquidity position with $2.07 billion in cash, cash equivalents, and marketable securities as of March 31, 2023, which it believes is sufficient for at least the next 12 months. While the company continues to invest heavily in R&D, the strong revenue growth suggests a positive trajectory towards its Alnylam P5x25 strategy.

Alnylam Pharmaceuticals, Inc. reported strong year-over-year growth in net product revenues for the third quarter and first nine months of 2022, driven by increased patient uptake of its key products ONPATTRO, GIVLAARI, OXLUMO, and AMVUTTRA. Total revenues increased by 41% and 20% for the respective periods. However, the company also experienced a significant increase in its net loss, primarily due to a substantial loss on the extinguishment of debt, increased R&D and SG&A expenses, and a marked increase in the fair value of its development derivative liability. The company has successfully issued $1.04 billion in convertible senior notes to bolster its financial position. Despite the widening net loss, Alnylam believes its current cash and cash equivalents are sufficient to fund operations for at least the next 12 months, supported by ongoing product sales and alliance revenues.

Alnylam Pharmaceuticals, Inc. reported total revenues of $224.8 million for the second quarter of 2022, a modest 2% increase year-over-year. This growth was primarily driven by a strong 33% increase in Net Product Revenues to $213.5 million, largely from ONPATTRO and GIVLAARI, partially offset by a significant decline in collaboration revenues, notably from Regeneron. The company's Net Loss widened by 46% to $277.4 million for the quarter, reflecting increased operating costs and expenses, particularly in research and development and selling, general, and administrative functions. Despite the widening net loss, the company maintains a substantial cash position and believes it has sufficient liquidity for the next 12 months, supported by ongoing product sales and collaborations. Investors should note the significant decrease in collaboration revenue and the increased operational expenses, while also monitoring the continued growth in product sales and the pipeline's advancement.

Alnylam Pharmaceuticals, Inc. reported total revenues of $213.3 million for the first quarter of 2022, a 20% increase compared to the same period in the previous year. This growth was primarily driven by a significant 38% increase in net product revenues, reaching $186.9 million, with ONPATTRO, GIVLAARI, and OXLUMO all showing strong year-over-year performance. The company experienced a net loss of $240.3 million for the quarter, widening from $200.3 million in Q1 2021, largely due to increased operating expenses, particularly in selling, general, and administrative categories, as well as higher interest expenses. Despite the increased net loss, Alnylam's cash position remains robust, with cash, cash equivalents, and marketable securities totaling $2.24 billion as of March 31, 2022, providing adequate runway for at least the next 12 months. The company continues to advance its pipeline, with notable progress in the vutrisiran New Drug Application (NDA) review by the FDA, which has an extended PDUFA goal date of July 14, 2022. OXLUMO also received FDA acceptance for a supplemental NDA for advanced PH1, with an action date in October 2022. These developments, coupled with strong commercial performance of its existing products, position Alnylam for continued growth, although strategic investments in R&D and SG&A are expected to impact near-term profitability.

Alnylam Pharmaceuticals, Inc. reported strong revenue growth in the third quarter and first nine months of 2021, driven by increasing net product revenues from its approved therapies ONPATTRO, GIVLAARI, and OXLUMO, alongside growth in collaboration revenues. Net product revenues increased by 68% year-over-year for the quarter and 86% for the nine-month period, reflecting successful commercial expansion and new product launches. Collaboration revenues saw a 51% increase for the nine months, primarily due to increased activity with Regeneron. Despite top-line growth, the company continues to incur significant operating losses, with a net loss of $204.5 million for the quarter and $594.4 million for the nine months. Research and development expenses remain substantial, increasing by 20% for the quarter to support a robust pipeline. The company ended the period with a solid cash position of approximately $2.33 billion, providing ample liquidity to advance its "Alnylam P5x25" strategy. The company is also progressing well with its late-stage clinical programs, notably vutrisiran, with positive topline results and ongoing submissions for regulatory approval.

Alnylam Pharmaceuticals, Inc. (ALNY) reported significant revenue growth in its second quarter of 2021, with total revenues nearly doubling year-over-year to $220.6 million. This increase was driven by strong performance in net product revenues, which more than doubled to $160.8 million, primarily from ONPATTRO and GIVLAARI, along with the new contribution from OXLUMO. Collaboration revenues also saw substantial growth, more than doubling to $59.4 million, largely due to increased activities with Regeneron Pharmaceuticals and Novartis AG. Despite the revenue growth, the company reported a net loss of $189.6 million for the quarter, a slight increase from the $179.2 million net loss in the prior year's second quarter. This was driven by higher operating costs and expenses, particularly in research and development, and increased interest expense related to its financing collaborations. The company's cash position remains strong, with $745.8 million in cash and cash equivalents, providing at least 12 months of operating runway according to management. Alnylam continues to advance its pipeline, with key updates on vutrisiran, including an NDA submission to the FDA and plans for an EU MAA based on positive Phase 3 data. The company's strategic therapeutic areas (STArs) and Alnylam P5x25 strategy remain on track, focusing on delivering transformative medicines and driving profitability.

Alnylam Pharmaceuticals reported a significant increase in total revenues for the first quarter of 2021, driven by strong growth in net product revenues from its marketed products ONPATTRO, GIVLAARI, and OXLUMO. Total revenues reached $177.6 million, a 79% increase year-over-year, primarily due to the expanding global reach of ONPATTRO and GIVLAARI, and the recent launch of OXLUMO. Collaboration revenues also saw a substantial boost, particularly from agreements with Regeneron and Novartis, indicating increased partnership activity and support for key products. Despite revenue growth, the company continued to report a net loss of $200.3 million for the quarter. This loss is attributed to significant investments in research and development ($185.9 million) and selling, general, and administrative expenses ($146.9 million), which increased to support its "Alnylam P5x25" strategy aimed at becoming a top five biotech company by market capitalization by 2025. The company's liquidity remains strong, with approximately $1.71 billion in cash, cash equivalents, and marketable securities as of March 31, 2021, which management believes is sufficient to support operations for at least the next 12 months.

This 10-Q filing for Alnylam Pharmaceuticals, Inc. as of November 5, 2020, highlights significant progress in its RNA interference (RNAi) therapeutics pipeline and commercialization efforts. The company reported strong revenue growth, driven by its marketed products ONPATTRO and GIVLAARI, which saw a substantial increase in net product revenues. Alnylam is executing on its "Alnylam 2020" strategy, aiming to become a multi-product, global biopharmaceutical company. The filing details advancements in key late-stage investigational programs, including lumasiran for primary hyperoxaluria type 1 (PH1), which has received positive opinions from regulatory bodies, and vutrisiran for ATTR amyloidosis. Financially, the company has secured significant funding through a strategic collaboration with Blackstone, providing capital to advance its pipeline. While Alnylam continues to incur operating losses, consistent with its development stage, the company expresses confidence in achieving a self-sustainable financial profile. The report also addresses the ongoing impact of the COVID-19 pandemic on operations and clinical trials, emphasizing a focus on maintaining business continuity and patient access to medicines.

Alnylam Pharmaceuticals reported robust top-line growth driven by strong ONPATTRO and GIVLAARI sales, with total revenues increasing by 133% year-over-year for the quarter and 161% for the six months ended June 30, 2020. This growth was bolstered by significant increases in net product revenues, up 103% and 132% respectively, and a substantial surge in collaboration revenues, up 308% and 300% respectively, primarily from the Regeneron and Vir collaborations. The company also secured a significant strategic financing collaboration with Blackstone, providing up to $2.00 billion in financing to accelerate pipeline advancement. Despite increased operating costs, particularly in R&D and SG&A supporting long-term growth, Alnylam demonstrated a reduction in its net loss by 18% for the quarter and 10% for the six months, reflecting improved operational efficiency and commercial execution. The company maintains a strong liquidity position, with substantial cash reserves, and is focused on advancing its multi-product RNAi therapeutics pipeline, highlighted by the positive regulatory progress for lumasiran.

Alnylam Pharmaceuticals, Inc. reported significant year-over-year revenue growth in the first quarter of 2020, primarily driven by strong performance of its approved RNAi therapeutics, ONPATTRO and GIVLAARI. Total revenues surged by 199% to $99.5 million, with net product revenues increasing by 174% to $71.9 million, largely due to the global expansion of ONPATTRO and the initial launch of GIVLAARI. Despite revenue growth, the company continues to invest heavily in research and development, which increased by 31% to $169.6 million, contributing to an operating loss of $210.2 million. Alnylam also secured a significant strategic financing collaboration with Blackstone, providing up to $2.0 billion to advance its RNAi therapeutic pipeline. The company noted potential impacts of the COVID-19 pandemic on its operations and clinical trials, but remains focused on advancing its pipeline and achieving its Alnylam 2020 goals.

Alnylam Pharmaceuticals, Inc. reported strong growth in product revenues for the third quarter and first nine months of 2019, primarily driven by its first commercial product, ONPATTRO®. Total revenues saw a substantial increase year-over-year. Despite this revenue growth, the company continues to incur significant operating losses, consistent with its business model focused on research and development of novel RNAi therapeutics. The company has a robust pipeline with several late-stage investigational programs, notably givosiran, for which an NDA was accepted by the FDA with Priority Review and an MAA filed with the EMA. Financially, Alnylam bolstered its cash position through a significant public offering and a strategic collaboration with Regeneron, which included a substantial upfront payment and stock purchase. The company's cash reserves remain strong, providing ample runway to fund its ongoing development and commercialization efforts under its Alnylam 2020 strategy. Management believes current resources are sufficient for multiple years, though continued investment in R&D and commercial capabilities is expected.

This Alnylam Pharmaceuticals 10-Q filing for the period ending June 30, 2019, highlights significant progress in commercializing ONPATTRO and advancing its pipeline, alongside substantial ongoing investment in research and development. The company reported a 50% increase in total revenues year-over-year, primarily driven by the launch of ONPATTRO, which generated $38.2 million in the second quarter and $64.5 million in the first half of the year. Despite this revenue growth, Alnylam continues to incur significant operating losses, with a net loss of $219.5 million for the quarter and $401.4 million for the first half, reflecting its heavy investment in R&D to support its "Alnylam 2020" strategy. A key development highlighted is the strong financial footing provided by a $400 million upfront payment and equity investment from Regeneron in May 2019, supplementing a $381.9 million net proceeds from a public offering in January 2019. These capital infusions, combined with existing cash reserves, are expected to fund operations for multiple years. The company is advancing several late-stage investigational programs, including givosiran for acute hepatic porphyria (AHP), which has received Priority Review from the FDA with a PDUFA date set for February 4, 2020. Investors should note the continued substantial R&D spending, the reliance on strategic partnerships, and the inherent risks associated with drug development and commercialization, as emphasized in the risk factors section.

Alnylam Pharmaceuticals, Inc. reported a significant increase in total revenues for the first quarter of 2019, reaching $33.3 million, a 52% rise compared to the same period last year. This growth is primarily driven by the successful commercialization of ONPATTRO®, their first RNAi therapeutic, which generated $26.3 million in net product revenues. While this marks a positive step, the company continues to operate at a loss, with an operating loss of $188.8 million and a net loss of $181.9 million for the quarter. This reflects substantial ongoing investment in research and development, crucial for advancing their broad pipeline of RNAi therapeutics across four strategic therapeutic areas. The company also bolstered its financial position through a $381.9 million public offering of common stock in January 2019 and entered into a significant global collaboration with Regeneron, which includes a $400 million upfront payment and potential future milestones, further strengthening their cash reserves.

This filing marks a significant inflection point for Alnylam Pharmaceuticals, Inc. (ALNY) as it transitions from a development-stage company to a commercial-stage biopharmaceutical company following the FDA approval and subsequent launch of ONPATTRO™ (patisiran) in August 2018 for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). The company reported its first product revenues, albeit modest, in the third quarter of 2018. Despite this commercial milestone, Alnylam continues to experience substantial operating losses, which are expected to persist in the foreseeable future due to ongoing significant investments in research and development (R&D) to advance its diverse RNA interference (RNAi) therapeutics pipeline across its four Strategic Therapeutic Areas (STArs). Key operational highlights include positive interim Phase 3 results for givosiran in acute hepatic porphyria (AHP) and progress in late-stage clinical development for other promising candidates like ALN-TTRsc02 and lumasiran. The company's strategic alliances with major pharmaceutical companies, such as Sanofi Genzyme and The Medicines Company, remain crucial for funding and advancing its pipeline, although revenue from these collaborations has decreased in the short term due to the adoption of new revenue recognition standards and the substantial completion of certain performance obligations. Alnylam's strong intellectual property portfolio underpins its strategy, and the company is focused on executing its "Alnylam 2020" strategy, aiming for three marketed products and ten late-stage clinical programs by the end of 2020.

This Q2 2018 report for Alnylam Pharmaceuticals highlights significant progress and key upcoming milestones, particularly concerning patisiran. The company received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorization for patisiran (ONPATTRO™) for hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). A decision from the European Commission is expected in September 2018, and the US FDA has an action date of August 11, 2018. Successful approval and launch could lead to product revenues starting in 2018. Operationally, Alnylam reported increased net revenues from collaborators, primarily driven by a milestone payment for the fitusiran Phase 3 program and work with Vir Biotechnology. However, operating expenses, particularly in research and development and general and administrative functions, also saw significant increases, reflecting ongoing pipeline advancement and preparations for potential commercialization. The company continues to invest heavily in R&D, essential for its RNAi therapeutic platform, while maintaining a substantial cash position, indicating it has sufficient resources for its near-term strategic goals.

This 10-Q filing for Alnylam Pharmaceuticals, Inc. (ALNY) for the period ending March 31, 2018, highlights significant progress in advancing its RNA interference (RNAi) therapeutic pipeline, particularly with the regulatory submissions for patisiran. Patisiran is nearing potential approval, with an action date from the FDA set for August 11, 2018. If approved, this would mark Alnylam's first commercial product, potentially generating significant revenue in 2018. The company continues to strengthen its strategic alliances, notably with Sanofi Genzyme and The Medicines Company, which provide crucial funding and development support. However, Alnylam continues to incur substantial operating losses, a typical characteristic of a clinical-stage biopharmaceutical company, and expects these losses to persist as it invests heavily in research and development.

This filing from Alnylam Pharmaceuticals, Inc. for the quarter ended September 30, 2017, highlights significant progress in their RNA interference (RNAi) therapeutic development. The company reported positive Phase 3 results for patisiran, its lead candidate for hereditary TTR-mediated amyloidosis (hATTR), with plans to submit regulatory applications by year-end 2017. Despite this positive news, the company also disclosed a temporary suspension of dosing for its fitusiran program due to a serious adverse event, which is undergoing regulatory review. Alnylam continues to advance its pipeline across three strategic therapeutic areas, aiming for three marketed products and ten clinical programs by 2020. Financially, Alnylam reported an increase in net revenues from collaborators, primarily driven by their partnership with Sanofi Genzyme. However, the company continues to incur substantial operating losses, as expected for a clinical-stage biopharmaceutical company, with a significant accumulated deficit. To support ongoing research and development and operational growth, Alnylam successfully raised substantial capital through a public offering in May 2017. The company believes its current cash position, along with anticipated collaboration revenues, will be sufficient to fund its operations for the next few years.

This 10-Q filing for Alnylam Pharmaceuticals, Inc. for the period ending June 30, 2017, highlights the company's continued progress in advancing its RNA interference (RNAi) therapeutic pipeline, particularly its Alnylam 2020 strategy. The company is focused on developing novel therapeutics for rare genetic diseases, cardio-metabolic diseases, and hepatic infectious diseases. Significant milestones include the advancement of patisiran towards a potential New Drug Application (NDA) submission by year-end 2017, initiation of the ATLAS Phase 3 program for fitusiran, and progress with givosiran, which received Breakthrough Therapy designation from the FDA. Financially, Alnylam reported an increase in net revenues from collaborators, primarily driven by its collaboration with Sanofi Genzyme. However, the company continues to incur significant operating losses due to substantial investments in research and development. Alnylam successfully raised $355.2 million in net proceeds from a public stock offering in May 2017, enhancing its liquidity and providing resources to support its ongoing development and transition towards a commercial-stage company. The company believes its current cash reserves and expected collaboration revenues will be sufficient for its strategic goals in the coming years.

This Alnylam Pharmaceuticals, Inc. (ALNY) 10-Q filing for the quarter ended March 31, 2017, highlights the company's continued focus on its novel RNA interference (RNAi) therapeutics. Alnylam is advancing a pipeline across three strategic therapeutic areas: Genetic Medicines, Cardio-Metabolic Diseases, and Hepatic Infectious Diseases, with a stated goal of having three marketed products and ten RNAi therapeutic clinical programs by the end of 2020. The company reported a significant increase in net revenues from collaborators, primarily driven by its partnerships with Sanofi Genzyme and The Medicines Company (MDCO). Financially, Alnylam continues to incur substantial operating losses, consistent with its R&D-intensive business model. While R&D expenses saw a slight decrease year-over-year, general and administrative expenses increased significantly due to investments in commercial and medical affairs infrastructure in preparation for potential product launches. The company maintains a robust cash position but faces ongoing risks associated with drug development, regulatory approvals, competition, and the need for future financing. The most advanced candidate, patisiran, is expected to report Phase 3 data in mid-2017, with potential regulatory filings planned by year-end if results are positive.

Alnylam Pharmaceuticals, Inc. reported its financial and operational results for the quarter and nine months ended September 30, 2016. The company's net revenues from collaborators showed an increase in the third quarter of 2016 compared to the prior year, driven by services under the Sanofi Genzyme agreement and a milestone payment. However, for the first nine months of 2016, revenues decreased primarily due to the completion of performance obligations with Monsanto and Takeda. Operating expenses significantly increased, with R&D expenses rising by 43% for both the three and nine-month periods, reflecting continued investment in the Genetic Medicine pipeline, including clinical trial and manufacturing costs, and increased compensation. General and administrative expenses also saw a substantial increase of 40% and 42% for the three and nine-month periods, respectively, largely due to higher compensation and stock-based compensation costs. This led to a net loss of $104.1 million for the third quarter and $297.2 million for the nine months, a considerable increase from the prior year periods. Despite the financial losses, the company ended the quarter with $168.5 million in cash and cash equivalents, supported by strong marketable securities holdings and access to financing.

Alnylam Pharmaceuticals, Inc. reported its financial results for the quarter and six months ended June 30, 2016. The company continues to experience significant operating losses, with a net loss of $90.1 million for the quarter and $193.1 million for the six months. This is largely driven by substantial investments in research and development, which increased by 24% and 44% respectively for the periods compared to the prior year, reflecting advancements in their RNAi therapeutic pipeline, particularly in Genetic Medicines. Despite the ongoing losses, Alnylam's cash position remains strong, with cash and cash equivalents totaling $271.1 million at quarter-end, bolstered by recent financing activities including a $150 million term loan facility. Key collaborations with Sanofi Genzyme and The Medicines Company continue to generate revenue, though overall collaboration revenues saw a decrease in the six-month period due to the completion of certain agreements. The company is advancing its 'Alnylam 2020' plan, aiming for three marketed products and ten clinical programs by the end of 2020. Progress in key therapeutic areas, including positive data from patisiran and fitusiran studies, highlights the ongoing development efforts. The company also announced an amendment to its lease for a manufacturing facility, extending the term through August 2022.

Alnylam Pharmaceuticals, Inc. (ALNY) reported its financial results for the quarter ended March 31, 2016. The company continued to experience significant operating losses, with a net loss of $102.97 million for the quarter. Revenue from collaborators decreased to $7.345 million from $18.537 million in the prior year period, primarily due to the completion of performance obligations under certain agreements. Despite the net loss, Alnylam maintains a strong cash position with $231.278 million in cash and cash equivalents and $977.012 million in marketable securities. The company is actively investing in research and development, with R&D expenses increasing to $96.273 million from $58.035 million year-over-year, reflecting advancements in its pipeline, particularly in Genetic Medicines. Significant upcoming events include expected data from the APOLLO Phase 3 trial for patisiran in mid-2017 and the initiation of two Phase 3 trials for fitusiran in mid-to-late 2016.

Alnylam Pharmaceuticals, Inc. reported its financial results for the quarter ended September 30, 2015, showcasing a strong balance sheet with total assets of $1.44 billion, bolstered by substantial cash and marketable securities. The company continues to invest heavily in research and development, with R&D expenses increasing by 48% for the quarter and 56% year-to-date, reflecting progress across its Genetic Medicines, Cardio-Metabolic Disease, and Hepatic Infectious Disease Strategic Therapeutic Areas (STArs). Despite significant operating losses typical for a clinical-stage biopharmaceutical company, Alnylam secured substantial funding through a public offering of $496.4 million in net proceeds in January 2015, alongside concurrent private placements with Genzyme. This financial strengthening is crucial for advancing its ambitious "Alnylam 2020" plan, which targets three marketed products and ten clinical-stage programs by 2020. Key partnerships, particularly with Genzyme, continue to be a significant driver, with Genzyme opting into the ALN-AT3 program. Investors should monitor clinical trial progress, collaboration milestones, and the company's ability to manage its substantial R&D investments.

Alnylam Pharmaceuticals, Inc. (ALNY) reported its financial results for the quarter and six months ended June 30, 2015. The company continues to invest heavily in research and development, as evidenced by a significant increase in R&D expenses year-over-year, reflecting its commitment to advancing its RNAi therapeutic pipeline across its three Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-Metabolic Disease, and Hepatic Infectious Disease. This investment is crucial for achieving its "Alnylam 2020" guidance, which aims for three marketed products and ten clinical programs by the end of 2020. Financially, Alnylam ended the period with a strong cash position, bolstered by a successful public offering in January 2015 that raised approximately $496.4 million in net proceeds. Despite ongoing operating losses, which are typical for a clinical-stage biopharmaceutical company, the company's substantial cash reserves and existing strategic alliances provide a runway to fund its ambitious development goals. Key partnerships, particularly with Genzyme and The Medicines Company, are critical for revenue generation and development progress. Investors should monitor the progress of key clinical trials, especially for patisiran and revusiran, and the potential for future collaborations and regulatory milestones.

Alnylam Pharmaceuticals, Inc. reported its first quarter 2015 financial results, showcasing significant progress in its cash position due to a successful public offering. The company raised approximately $496.4 million in net proceeds from the offering in January 2015, bolstering its cash and cash equivalents to $306.6 million as of March 31, 2015. This strong liquidity provides substantial runway to fund its ambitious "Alnylam 2020" plan, which aims for three marketed products and ten clinical programs by 2020. Operationally, Alnylam reported increased net revenues from collaborators to $18.5 million, up from $8.3 million in the prior year's quarter, driven by contributions from Monsanto, Takeda, and Genzyme. While research and development expenses rose to $58.0 million, reflecting pipeline advancement, the overall operating expenses decreased significantly year-over-year due to the absence of a large in-process R&D charge recorded in the prior year's quarter. The company continues to advance its diverse pipeline of RNAi therapeutics across its Genetic Medicine, Cardio-Metabolic Disease, and Hepatic Infectious Disease therapeutic areas.

This filing is an amendment (Amendment No. 1) to Alnylam Pharmaceuticals, Inc.'s previously filed Quarterly Report on Form 10-Q for the period ended March 31, 2014. The amendment's sole purpose is to include the Fifth Amendment to Lease, dated March 27, 2014, as an exhibit (Exhibit 10.5). This lease amendment was inadvertently omitted from the original filing. The company states that the material terms of this lease amendment were already disclosed in a prior Form 8-K filing on April 2, 2014. Investors should note that this amendment does not alter any other financial or operational disclosures made in the original Form 10-Q filing. The amendment is effective as of the original filing date and does not incorporate any information or events that have occurred since then. Therefore, for a comprehensive understanding of Alnylam's financial performance and operational status as of March 31, 2014, investors should refer to the original Form 10-Q filing.

Alnylam Pharmaceuticals, Inc. reported a strong increase in cash and cash equivalents, reaching $82.7 million by September 30, 2014, up from $53.2 million at the end of 2013. This financial strengthening is largely attributed to a significant $700 million cash infusion from Genzyme in February 2014 as part of a strategic collaboration, alongside an additional $23 million Genzyme investment later in March. Despite this robust financing, the company continued to operate at a loss, with a net loss of $44.0 million for the third quarter and $339.0 million for the first nine months of 2014, reflecting substantial ongoing investment in research and development. The company's R&D expenses increased significantly, particularly due to a $220.8 million charge for in-process R&D related to the acquisition of Sirna Therapeutics' RNAi assets. Alnylam is advancing its core product strategy, the "Alnylam 5x15," with several candidates in clinical development, including patisiran (ALN-TTR02) in Phase 3 trials and revusiran (ALN-TTRsc) in Phase 2. The Genzyme collaboration, a key strategic alliance, is central to the company's global commercialization efforts for its genetic medicine programs.

Alnylam Pharmaceuticals, Inc. (ALNY) reported its financial results for the quarter and six months ended June 30, 2014. The company significantly increased its cash position, primarily driven by a substantial $700 million cash infusion from Genzyme as part of a strategic collaboration. This collaboration also involves Genzyme acquiring a significant equity stake in Alnylam. Financially, Alnylam continues to operate at a loss, with a net loss of $44.1 million for the quarter and $295.0 million for the six-month period, reflecting ongoing investments in research and development. A notable item impacting expenses was a substantial charge of $220.8 million recognized as in-process research and development related to the acquisition of Sirna Therapeutics' RNAi assets from Merck. Despite the net loss, the company's balance sheet strengthened considerably, ending the period with over $955 million in cash, cash equivalents, and marketable securities, providing ample runway for its development programs.

Alnylam Pharmaceuticals, Inc. (ALNY) reported its first quarter 2014 financial results, showcasing significant advancements in its RNA interference (RNAi) therapeutic pipeline and a substantial strengthening of its financial position. The company's strategic focus on developing novel RNAi therapeutics, particularly under its "Alnylam 5x15" program, continues to drive its R&D efforts. The period was marked by a major strategic collaboration with Genzyme, a Sanofi company, which significantly bolstered ALNY's cash reserves and provided substantial validation for its genetic medicine pipeline. Financially, Alnylam reported a substantial increase in cash and cash equivalents, largely due to the upfront payment and equity investment from Genzyme. While the company continues to incur significant operating losses, driven by substantial investments in research and development, particularly a notable in-process R&D charge related to the Sirna acquisition, the strong liquidity position provides ample runway for continued development. The Genzyme collaboration, alongside other strategic alliances, is expected to be a primary source of future revenue through milestone payments and royalties.

Alnylam Pharmaceuticals, Inc. reported its financial results for the quarterly period ended September 30, 2013. The company continues to operate at a net loss, with a loss of $29.7 million for the third quarter and $56.9 million for the first nine months of the year. This reflects significant ongoing investment in research and development, which increased by 56% and 25% year-over-year for the respective periods. Despite the losses, Alnylam bolstered its financial position by raising approximately $173.6 million in net proceeds from a public offering in January 2013, contributing to a total cash and marketable securities balance of $367.1 million as of September 30, 2013. Operationally, the company is advancing its 'Alnylam 5x15' strategy, focusing on five RNAi therapeutic programs in clinical development by the end of 2015. Key updates include positive interim results from the Phase II trial of patisiran (ALN-TTR02) for transthyretin-mediated amyloidosis (ATTR) and promising early data for ALN-TTRsc, demonstrating human translation of its GalNAc-siRNA conjugate platform. The company also filed an application to initiate a Phase I clinical trial for ALN-AT3 and identified a development candidate for ALN-AS1. Revenue from research collaborators decreased compared to the prior year, primarily due to the completion of the Roche/Arrowhead alliance, though this was partially offset by recognition of deferred revenue from the Cubist agreement termination and new revenues from Monsanto and The Medicines Company.

Alnylam Pharmaceuticals, Inc. (ALNY) reported its financial results for the quarter ended June 30, 2013. The company continued to advance its RNAi therapeutic pipeline, with a focus on its core product strategy, 'Alnylam 5x15.' Significant progress was noted in the ALN-TTR program, with promising interim results from the Phase II clinical trial of ALN-TTR02 demonstrating dose-dependent and durable knockdown of serum TTR levels. Additionally, ALN-TTRsc showed robust knockdown in healthy volunteers from its Phase I trial. The company secured substantial proceeds from a public offering in January 2013, bolstering its cash position to $24.975 million and overall liquidity with marketable securities. While net revenues from research collaborators decreased year-over-year, primarily due to the completion of obligations under the Roche/Arrowhead alliance, this was partially offset by new revenues from agreements with Monsanto and The Medicines Company (MDCO). Alnylam also reported increased research and development expenses, reflecting continued investment in its pipeline and drug delivery technologies, while general and administrative expenses decreased due to the resolution of litigation. Despite ongoing net losses, Alnylam's substantial cash reserves and strategic alliances provide a runway for continued development. The company's focus on a genetically defined target strategy and its robust intellectual property portfolio position it to navigate the competitive biopharmaceutical landscape.

This amended 10-Q filing from Alnylam Pharmaceuticals, Inc. for the quarter ended March 31, 2013, primarily serves to provide an updated Exhibit 10.2, a License and Collaboration Agreement with The Medicines Company dated February 3, 2013. Investors should note that this amendment does not alter the financial performance or operational updates previously reported in the original filing of May 7, 2013. The core financial and business disclosures remain as previously filed. While specific financial figures for the quarter are not detailed in this amendment, the filing confirms Alnylam's status as an accelerated filer. Investors interested in the specifics of the collaboration with The Medicines Company will need to review the revised Exhibit 10.2, which has undergone confidential treatment for certain sections, indicating the sensitive nature of the agreement's terms. The overall focus of this amendment is on regulatory compliance and the clarification of contractual documentation rather than reporting new financial results.

Alnylam Pharmaceuticals, Inc. reported its financial results for the quarter ended March 31, 2013. The company continues to operate at a loss, with a net loss of $9.0 million for the quarter, an improvement from $11.4 million in the same period last year. This improvement was largely driven by increased revenue from new and existing collaborations, particularly offset by a significant decrease in revenue from the Roche/Arrowhead alliance. The company successfully raised approximately $173.6 million in net proceeds from a public offering in January 2013, bolstering its cash position to $97.8 million.

Alnylam Pharmaceuticals, Inc. reported its financial and operational results for the quarter and nine months ended September 30, 2012. The company continues to focus on its core 'Alnylam 5x15' strategy, aiming to have five RNAi therapeutic programs in clinical development by the end of 2015. During this period, Alnylam raised approximately $86.8 million in net proceeds from a public offering in February 2012, bolstering its cash position. The company is advancing its lead programs, ALN-TTR02 for transthyretin-mediated amyloidosis (ATTR) and ALN-AT3 for hemophilia, with ALN-TTR02 showing robust TTR protein knockdown in Phase I trials and a Phase II trial initiated. Significant developments also include progress in pre-clinical stages for other core programs and continued partner-based development. The company also reported progress in significant litigation matters, including the ongoing Tekmira patent infringement case. While revenues from research collaborators saw a decline due to the completion of performance obligations under the Roche/Arrowhead alliance, the company remains focused on advancing its pipeline. Operating expenses were impacted by a strategic corporate restructuring in January 2012, which reduced the workforce by approximately 33% to lower operating expenses. Despite incurring net losses, Alnylam believes its current cash and marketable securities, combined with expected alliance revenues, will be sufficient to fund operations through at least the end of 2014. Key subsequent events include Regulus Therapeutics' IPO in October 2012 and a license and collaboration agreement with Genzyme for ALN-TTR therapeutics.

Alnylam Pharmaceuticals, Inc. (ALNY) filed its quarterly report for the period ending June 30, 2012, on August 8, 2012. The company reported a net loss of $12.96 million for the second quarter, compared to a net loss of $13.82 million in the same period of 2011. For the six months ended June 30, 2012, the net loss was $24.32 million, an improvement from $30.11 million in the prior year period. This reduction in net loss was primarily driven by lower research and development expenses. The company's financial position strengthened with total assets reaching $318.48 million at June 30, 2012, up from $281.92 million at December 31, 2011. This increase was largely due to a significant rise in marketable securities and an increase in cash and cash equivalents. Notably, Alnylam successfully raised approximately $86.8 million in net proceeds from a public offering in February 2012, which bolstered its cash reserves and is intended to fund pipeline advancement. However, cash and cash equivalents decreased to $48.27 million from $70.23 million at the end of the previous quarter, indicating significant cash burn from operations.

Alnylam Pharmaceuticals, Inc. reported its first quarter 2012 financial results, indicating continued investment in its RNAi therapeutic pipeline. The company's net revenue from research collaborators remained relatively stable year-over-year, primarily driven by its alliances with Roche/Arrowhead and Takeda. However, operating expenses, particularly in research and development, saw a decrease compared to the prior year, largely due to a strategic restructuring and workforce reduction implemented in early 2012, which is expected to yield significant cost savings throughout the year. Financially, Alnylam ended the quarter with a solid cash position, bolstered by a public offering of common stock in February 2012 that raised approximately $86.8 million in net proceeds. This capital infusion is earmarked for advancing its clinical pipeline, including the ALN-TTR02 and ALN-APC programs. Despite ongoing net losses, typical for an early-stage biopharmaceutical company, the company appears well-positioned to fund its operations through at least the end of 2013, with potential for further funding through existing or new strategic alliances.

This 10-Q filing for ALNYLAM PHARMACEUTICALS, INC. (ALNY) as of November 3, 2011, covers the unaudited financial results for the nine months ended September 30, 2011. Investors should note the company is in the development stage, as indicated by ongoing losses and significant research and development expenses. The financial statements detail the company's financial position, operational performance, and cash flows, reflecting its investment in pipeline development and early-stage commercialization efforts. While no specific revenue figures or profit/loss details are provided in this overview of the filing's structure, the focus of the MD&A section will be on the company's financial condition, results of operations, and market risk. The risk factors section is particularly important for understanding the inherent uncertainties and potential challenges associated with a biopharmaceutical company at this stage of its lifecycle.

Alnylam Pharmaceuticals, Inc. (ALNY) reported its financial results for the quarter and six months ended June 30, 2011. The company continues to operate at a loss, a common characteristic of early-stage biopharmaceutical firms. For the six months ended June 30, 2011, Alnylam reported a net loss of $30.1 million, a slight increase from the $26.9 million net loss in the same period of 2010. Total net revenues from research collaborators decreased to $41.5 million for the six months ended June 30, 2011, down from $51.1 million in the prior year, primarily due to the planned completion of the Novartis collaboration. Operating expenses also decreased slightly, driven by lower general and administrative costs, including reduced legal expenses. The company's balance sheet shows a decrease in cash and cash equivalents and marketable securities, totaling $316.0 million at June 30, 2011, down from $349.9 million at December 31, 2010. This decrease is largely attributable to net cash used in operating activities, which was $32.9 million for the first six months of 2011, despite net cash provided by investing activities from the sale of marketable securities. Alnylam ended the period with $136.6 million in stockholders' equity. The company highlights its core "Alnylam 5x15" product strategy and the advancement of key programs like ALN-TTR and ALN-PCS, with ALN-PCS filing a clinical trial application in the UK. Investors should monitor progress in clinical trials, partnership developments, and cash burn rate, as the company remains in a pre-revenue stage.

Alnylam Pharmaceuticals, Inc. (ALNY) filed its Form 10-Q for the period ending March 31, 2011. As an early-stage biopharmaceutical company, Alnylam's financial performance continues to be heavily influenced by its research and development activities and progress in advancing its pipeline of RNAi therapeutics. Investors should note that the company is not yet generating significant product revenue, and therefore, its financial results reflect substantial investments in drug development and operational expenses. The report details the company's financial position and operational results for the first quarter of 2011. Key areas to focus on include the company's cash burn rate, its progress in clinical trials, strategic partnerships, and its ability to secure necessary funding to support its ongoing development efforts. The absence of product sales means that profitability is not an immediate concern, but rather the efficient deployment of capital towards achieving key development milestones and regulatory approvals is paramount.

This 10-Q filing for ALNYLAM PHARMACEUTICALS, INC. (ALNY) for the period ending September 30, 2010, provides investors with an unaudited look at the company's financial position and operational results for the third quarter and the first nine months of 2010. As a clinical-stage biopharmaceutical company, ALNY's financial performance is heavily influenced by its research and development activities, significant operating losses, and its reliance on cash reserves and potential future financing. Investors should pay close attention to the company's cash burn rate, the progress of its drug development pipeline, and any updates on strategic partnerships or collaborations, as these factors will be critical to its long-term viability and potential for future revenue generation.